Laboratorium Obrazowania Molekularnego i Rozwoju Technologii Sp. z o.o
Laboratorium Obrazowania Molekularnego i Rozwoju Technologii Sp. z o.o is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 1 of 1 trials · Latest update first
Multicentre Evaluation of Clinical Applications of Innovative PET/MRI with a 68Ga-PSMA-11 Radiotracer when Planning a Personalised Therapy in Prostate Cancer Patients
Sponsor Medical University Of Bialystok
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The absence of a uniform histopathological reference standard for all detected lesions prevented reliable estimation of absolute sensitivity and specificity and introduced potential partial-verification bias.
- Site heterogeneity in multidisciplinary-team decision-making was a limitation; the Bydgoszcz site was excluded from final analysis because of its homogeneous patient population, with sensitivity analyses not changing the conclusions.
- Protocol deviations and missing data for selected variables, including radiation dose, were reported limitations.
These findings describe the trial, not the service provider’s performance or responsibility.
Questions about this trial experience
What services are recorded for Laboratorium Obrazowania Molekularnego i Rozwoju Technologii Sp. z o.o?
The 2026-10-09 snapshot links Laboratorium Obrazowania Molekularnego i Rozwoju Technologii Sp. z o.o to 1 distinct CTIS trials. Recorded services include performance of PET/CT and PET/MR examinations. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Laboratorium Obrazowania Molekularnego i Rozwoju Technologii Sp. z o.o?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Urology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Laboratorium Obrazowania Molekularnego i Rozwoju Technologii Sp. z o.o conducted?
The linked trials record locations in 1 country, including Poland. These are trial locations, not confirmed office locations or countries where Laboratorium Obrazowania Molekularnego i Rozwoju Technologii Sp. z o.o delivered services.
What can this page tell me about Laboratorium Obrazowania Molekularnego i Rozwoju Technologii Sp. z o.o's trial experience?
Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Laboratorium Obrazowania Molekularnego i Rozwoju Technologii Sp. z o.o. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Laboratorium Obrazowania Molekularnego i Rozwoju Technologii Sp. z o.o.